Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis

Table 4

Scenario analysis generic pricing imatinib.

Scenario	A: base-case			B: imatinib 60% of original cost			C: imatinib 40% of original cost
	Cost (US$)	Effectiveness (QALYs)	ICUR (US$/QALY)	Cost (US$)	Effectiveness (QALYs)	ICUR (US$/QALY)	Cost (US$)	Effectiveness (QALYs)	ICUR (US$/QALY)
Chemo	94,492	3.47		94,492	3.47		94,492	3.47
Imatinib → chemo/SCT	749,272	7.29	171,700	510,214	7.29	109,000	390,685	7.29	77,600
Imatinib → nilotinib → chemo/SCT	965,597	8.14	253,500	726,539	8.14	253,500	607,010	8.14	253,500
Imatinib → dasatinib → chemo/SCT	1,099,065	8.43	—	860,007	8.43	463,800	740,477	8.43	463,800
Nilotinib → dasatinib → chemo/SCT	1,200,921	8.67	445,100	1,200,921	8.67	1,415,200	1,200,921	8.67	1,911,400

Chemo: chemotherapy; QALY: quality-adjusted life years; SCT: stem-cell transplantation.